A socially distanced podcast with James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) previewing the October issue of DTB. This includes an editorial that discusses the harms caused by medicines and medical devices and highlights concerns over proposals to speed up the UK licensing process for medicines. The editors talk about an article that looks at the influence of pharmaceutical marketing. They also review three new medicines used to prevent migraines. This month's case report involves a patient with rheumatoid arthritis who received latent tuberculosis infection treatment prior to treatment with a biologic agent, and developed shock with resistant hypotension on re-exposure to rifampicin.

Read the full issue: https://dtb.bmj.com/content/58/10